FinTechFunding

Imugene: Progresses VAXINIA trial in December quarter

Imugene Progresses VAXINIA trial in December quarter

  • Imugene (IMU) has taken another step forward in its efforts to treat and eradicate tumours in cancer patients
  • During the three months to December 31, 2022 the company saw its first patient dosed in VAXINIA intravenous (IV) cohort two
  • The company also added to its management team during the quarter, with the appointments of Dr Giovanni Selvaggi and Paul Wright
  • The company says it’s well funded to continue its clinical pipeline and operations, with cash at bank sitting at $161.9 million
  • IMU shares were down 3.33 per cent, trading at 14.5 cents at 3:45 pm AEDT
Previous article
Lake Resources: Ends quarter with $133m cash balance
Next article
Patrys: Receives $3.35m R&D tax incentive refund
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

NYSE Parent Invests $600M in Polymarket, Strengthening Market Position

This significant investment signals confidence in the future of predictive markets.Highlights: NYSE's parent company allocates $600M to Polymarket.Investment...
FinTech

Nexi Expands SEPA Direct Debit with Danish Banks, Enhancing Payments Integration

Nexi's collaboration with Danish banks aims to strengthen payment services across Europe.Highlights: Nexi partners with several Danish banks...
FinTech

Lloyds Confirms App Glitch Exposed Data of Almost Half a Million Customers

The significant data breach prompts concerns over customer privacy.Highlights: Lloyds Banking Group admits to a data breach affecting...
FinTech

Mastercard Restricts Sale of Nets Payments Unit Purchased for $3.2 Billion

Mastercard looks to divest its Nets payments segment as part of strategic realignment.Highlights: Mastercard is seeking to sell...